{
    "relation": [
        [
            "Company",
            "Amarin",
            "Hutchinson",
            "Ellie Mae",
            "Eagle Rock Energy Partners",
            "Teva Pharmaceuticals"
        ],
        [
            "Nov. 1",
            "$1.64",
            "$3.03",
            "$24.03",
            "$6.16",
            "$37.12"
        ],
        [
            "Weekly Loss",
            "25%",
            "23%",
            "21%",
            "16%",
            "11%"
        ]
    ],
    "pageTitle": "5 of Last Week's Biggest Losers - DailyFinance",
    "title": "",
    "url": "http://www.dailyfinance.com/2013/11/03/5-of-last-weeks-biggest-losers/",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988930.94/warc/CC-MAIN-20150728002308-00278-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 390969679,
    "recordOffset": 390944549,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{23679=Nov. 1, 25084=Let's start with Amarin. The former high-flying biotech continues its dramatic fade in 2013. The stock has shed nearly 80% of its value this year, and it's now trading at its lowest level in more than three years. This week's 25% blow came after the Food and Drug Administration announced that its triglyceride-reducing drug Vascepa may not merit approval in lowering the cardiovascular problems in select patients. It also didn't help that FBR Capital initiated coverage on Amarin with a ho-hum \"market perform\" rating and a price target that was below where it was trading at the time. Amarin did close out the week below FBR's $2 price target., 31019=Copyright \u00a9 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.}",
    "textBeforeTable": "There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. \u00d7 Read More \u00bb %BloggerLongBio% About View All Posts \u00bb What Will Your Summer Vacation Really Cost You? What You Need to Know First About Taking on New Credit How to Waste Less Food, Money Recent Posts Updated Nov 3rd 2013 7:02AM Nov 3rd 2013 7:01AM Rick Munarriz, The Motley Fool --> Rick Munarriz, The Motley Fool",
    "textAfterTable": "Source: Barron's. Let's start with Amarin. The former high-flying biotech continues its dramatic fade in 2013. The stock has shed nearly 80% of its value this year, and it's now trading at its lowest level in more than three years. This week's 25% blow came after the Food and Drug Administration announced that its triglyceride-reducing drug Vascepa may not merit approval in lowering the cardiovascular problems in select patients. It also didn't help that FBR Capital initiated coverage on Amarin with a ho-hum \"market perform\" rating and a price target that was below where it was trading at the time. Amarin did close out the week below FBR's $2 price target. Hutchinson's drop came largely on Friday, after it posted an adjusted loss of $0.40 a share on flat revenue growth. Analysts were expecting only $0.24 a share in red ink, making this the second consecutive quarter where Hutchinson delivers a much larger deficit than Wall Street was forecasting. The future won't get a whole lot better. Hutchinson sees suspension assemblies for the new quarter clocking in essentially flat sequentially. Ellie Mae investors were in dismay after the mortgage-processing solutions provider posted disappointing financial results. Ellie Mae was smacked down by a drop in mortgage origination volume. It tried to overcome the sloppy results with the acquisition of MortgageCEO -- a provider of CRM and marketing solutions",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}